Immuron Ltd has released a press release.
Preliminary Final Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immuron
- Voluntary Suspension
- Pause in Trading
- IMM124E May Offer New Modality for Inhibition of SARS-CoV-2
- Immuron SARS-CoV-2 Research Agreement with Monash University
- Immuron Receives AUD $358,280 R&D Tax Concession Refund
Later from Immuron
- Immuron planned Acquisition of R&D Vaccine Company
- Reinstatement to Official Quotation
- IMM124E Demonstrates Antiviral T-Cell Immunity
- US DoD Naval Medical Research Center Clinical Update
- US DoD Travelan Clinical Update
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron